ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
The Association Between Adiponectin Gene Polymorphism (rs1501299) and Metabolic Syndrome.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the allelic genotypes of the adiponectin (APN) gene polymorphisms (rs1501299) and its association with APN level among Mets patients. Methods: A total of 410 patients with Mets and 203 healthy subjects were included in the study. The serum APN levels of the subjects were detected using enzyme-linked immunosorbent assay. The polymorphisms of the G/T gene at the rs1501299 locus of the APN gene were detected using restriction fragment length polymorphism polymerase chain reaction technology. Results: The serum APN levels were significantly lower in Mets patients than in the control group (15.0 ± 4.9 mg/L vs 27.2 ± 6.5 mg/L, p < 0.05). The distribution of the three genotypes at the rs1501299 locus was statistically different between the Mets patients and the control group (GG, GT, and TT, p < 0.05), and the frequencies of the T alleles were higher in the Mets patients than in control group (GT and TT, p < 0.05). Logistic regression analysis showed that the study subjects with the T allele had a higher risk of Mets than those with the G allele (OR = 1.85, p < 0.05). The risk of Mets was higher in GT and TT genotypes compared to in GG genotypes (OR = 1.43; OR = 2.14 vs OR = 1.00 ref). Similarly, it increased after combining GT and GG genotypes (OR = 1.73, p < 0.05). The APN levels in the GT (14.3 ± 5.3 mg/L) and TT (13.4 ± 5.4 mg/L) genotypes of the study subjects were lower than those of the GG genotype (15.5 ± 4.8 mg/L, p < 0.05). Conclusion: The occurrence of Mets may be associated with genetic variants at the rs1501299 locus, especially for individuals with G to T variants that reduce APN levels and lead to a higher risk of developing Mets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.